HSTO vs. PRFX, TCBP, TFFP, SRNE, SMFL, BLPH, SEEL, NEXI, VAXX, and SCPS
Should you be buying Histogen stock or one of its competitors? The main competitors of Histogen include PainReform (PRFX), TC Biopharm (TCBP), TFF Pharmaceuticals (TFFP), Sorrento Therapeutics (SRNE), Smart for Life (SMFL), Bellerophon Therapeutics (BLPH), Seelos Therapeutics (SEEL), NexImmune (NEXI), Vaxxinity (VAXX), and Scopus BioPharma (SCPS). These companies are all part of the "pharmaceutical products" industry.
Histogen vs.
Histogen (NASDAQ:HSTO) and PainReform (NASDAQ:PRFX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, community ranking, media sentiment and analyst recommendations.
Histogen received 4 more outperform votes than PainReform when rated by MarketBeat users. However, 75.00% of users gave PainReform an outperform vote while only 58.33% of users gave Histogen an outperform vote.
Histogen's return on equity of 0.00% beat PainReform's return on equity.
Histogen has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, PainReform has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.
In the previous week, Histogen's average media sentiment score of 0.00 equaled PainReform'saverage media sentiment score.
37.3% of PainReform shares are held by institutional investors. 3.3% of Histogen shares are held by insiders. Comparatively, 34.4% of PainReform shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
PainReform has lower revenue, but higher earnings than Histogen. PainReform is trading at a lower price-to-earnings ratio than Histogen, indicating that it is currently the more affordable of the two stocks.
PainReform has a consensus price target of $8.00, indicating a potential upside of 167.56%. Given PainReform's stronger consensus rating and higher probable upside, analysts clearly believe PainReform is more favorable than Histogen.
Summary
Histogen beats PainReform on 7 of the 13 factors compared between the two stocks.
Get Histogen News Delivered to You Automatically
Sign up to receive the latest news and ratings for HSTO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Histogen Competitors List
Related Companies and Tools
This page (NASDAQ:HSTO) was last updated on 1/21/2025 by MarketBeat.com Staff
Free HSTO Stock Alerts